immunity News and Research

RSS

Modeling the risk of SARS-CoV-2 outbreaks upon lifting non-pharmaceutical interventions (NPIs)

In a paper recently uploaded to the preprint server medRxiv* by Sachak-Patwa et al. (May 22nd, 2021), mathematical models are developed to assess the probability and impact of such localized outbreaks, accounting for changing general immunity levels in the population as vaccines are distributed.

25 May 2021

Person infected with SARS-CoV-2 can transmit infection to three to five other people

What started as the preliminary analysis of routine laboratory data has since evolved into the largest-ever study of viral load levels in patients with SARS-CoV-2.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Healthcare workers were three times more likely to get infected by COVID-19, shows study

A study of healthcare workers shows they were three times more likely to become infected during the COVID-19 pandemic compared to the general population. Around one in five of workers who were infected were asymptomatic and unaware they had COVID-19.

25 May 2021

Do mixed COVID-19 vaccines provide immunity?

The initial results of the CombivacS trial found that the antibody levels in individuals increased by 150 times when the Pfizer messenger ribonucleic acid (mRNA) vaccine was given after a first dose of the AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, with only mild common side effects.

24 May 2021

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Antibodies, Antibody, Assay, Coronavirus, Efficacy, Healthcare, Pandemic, Protein, Receptor, Research, Vaccine, Virus, Coronavirus Disease COVID-19,

24 May 2021

Novel natural compounds may help treat COVID-19, study suggests

A new study in the journal Chemistry Europe reports two natural compounds identified by virtual screening and computational modeling as having great promise for the development of drugs against SARS-CoV-2.

24 May 2021

Mild cases of COVID-19 provide lasting antibody protection, shows study

Months after recovering from mild cases of COVID-19, people still have immune cells in their body pumping out antibodies against the virus that causes COVID-19, according to a study from researchers at Washington University School of Medicine in St. Louis. Such cells could persist for a lifetime, churning out antibodies all the while.

24 May 2021

Could saffron be an effective supplement for helping manage COVID-19?

A new study, published in the journal Cell Press, explores the potential use of saffron (Crocus sativus L.) as a drug supplement for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19).

24 May 2021

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.

24 May 2021

STING agonist diABZI shows promise against SARS-CoV-2 variants

COVID-19 vaccines are the most effective way to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. For people who are already infected, new research suggests the small molecule stimulator of interferon genes (STING) agonist-1, diABZI, may be effective in controlling SARS-CoV-2 infection — including those caused by variants.

23 May 2021

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

In Munich, Germany, scientists at Ludwig Maximilian University studied temporal adaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to better understand protection against re-infection. They found functional properties of persisting memory B specific to SARS-CoV-2 may help in protect against the virus.

23 May 2021

SARS-CoV-2 B.1.1.7 and B.1.351 variants exhibit enhanced affinity towards the ACE2 receptor

In a short correspondence paper recently uploaded to the Lancet by Ramanathan, Muthukumar et al. (May 19th, 2021) the affinity of labeled SARS-CoV-2 spike receptor-binding domain proteins sourced from each of these two variants of concern towards human angiotensin-converting enzyme 2 (ACE2) recombinant proteins is investigated using microscale thermophoresis, confirming the enhanced affinity towards the receptor observed in other studies.

22 May 2021

SARS-CoV-2 virus persistence in immunocompromised individuals

Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests are frequently obtained from individuals that have already recovered from the virus in the past. They have therefore undergone seroconversion and bear the expected antibodies.

22 May 2021

High seroprevalence in Peruvian population recovering from SARS-CoV-2 infection

By the middle of 2020, Iquitos, Peru, had the highest number of SARS-CoV-2 antibodies in the world. Despite natural immunity, the city experienced a second coronavirus wave, with reinfections possibly owing to the P.1 variant.

22 May 2021

Australian discovery could speed up SARS-CoV-2 vaccine development

To address this gap, researchers from Australia recently examined the relationship between levels of in vitro neutralization and the observed protection obtained from SARS-CoV-2 infection. They used data from 7 currently available vaccines and convalescent cohorts. Their research is published in the journal Nature Medicine.

22 May 2021

When COVID-19 is severe, rogue antibodies attack body tissues and organs

The study, published in the journal Nature, sheds light on the disease mechanism of COVID-19 and how the virus causes a faulty immune system.

21 May 2021

Plant-based vaccine against SARS-CoV-2 shows promise

Researchers at Canadian biotechnology company Medicago report that Phase 1 trials of a plant-based vaccine for SARS-CoV-2 are underway and showing promise.

21 May 2021

immunity News and Research

Modeling the risk of SARS-CoV-2 outbreaks upon lifting non-pharmaceutical interventions (NPIs)

Person infected with SARS-CoV-2 can transmit infection to three to five other people

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Healthcare workers were three times more likely to get infected by COVID-19, shows study

Do mixed COVID-19 vaccines provide immunity?

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Novel natural compounds may help treat COVID-19, study suggests

Mild cases of COVID-19 provide lasting antibody protection, shows study

Could saffron be an effective supplement for helping manage COVID-19?

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

STING agonist diABZI shows promise against SARS-CoV-2 variants

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

SARS-CoV-2 B.1.1.7 and B.1.351 variants exhibit enhanced affinity towards the ACE2 receptor

SARS-CoV-2 virus persistence in immunocompromised individuals

High seroprevalence in Peruvian population recovering from SARS-CoV-2 infection

Australian discovery could speed up SARS-CoV-2 vaccine development

When COVID-19 is severe, rogue antibodies attack body tissues and organs

Plant-based vaccine against SARS-CoV-2 shows promise

Industry Focus eBook - Cell biology (5th edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News